durvalumab + monalizumab + cetuximab

This is an investigational combination of three monoclonal antibodies: durvalumab (an anti-PD-L1 antibody developed as MEDI4736), monalizumab (an anti-NKG2A antibody, also known as IPH2201), and cetuximab (an anti-EGFR antibody, marketed as Erbitux). The combination is designed to target three distinct immune pathways and has shown anti-tumor activity in early clinical studies, particularly in solid tumors such as colorectal cancer (CRC) and recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)[1][5]. Durvalumab blocks PD-L1, enhancing T-cell mediated anti-tumor immunity; monalizumab relieves NK cells and some T cells from NKG2A-mediated inhibition, improving immune cell activation; cetuximab blocks EGFR and also triggers antibody-dependent cellular cytotoxicity (ADCC) which is further enhanced by monalizumab[2][3][5][6].

Other names

durvalumab + monalizumab + cetuximab